Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019197 · ClinicalTrials.gov registry record · Phase 2
Effects of Semaglutide in HIV-Associated Lipohypertrophy
A Phase 2 study of Obesity and HIV/AIDS, sponsored by Case Western Reserve University.
- Active
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 2
- Study locations
NCT04019197 is a Phase 2 study of Obesity and HIV/AIDS that is active but no longer recruiting, run by Case Western Reserve University. The registered enrollment target is 108 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04019197, a Phase 2 study of Obesity and HIV/AIDS, is active but no longer recruiting, sponsored by Case Western Reserve University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide Injectable Product
Study Locations (2)
Ohio
- Case Western Reserve University - Cleveland
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019197
The ClinicalTrials.gov registry entry for NCT04019197 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04019197 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, South Carolina.
Frequently Asked Questions
What is clinical trial NCT04019197 about?
NCT04019197 is a clinical study titled "Effects of Semaglutide in HIV-Associated Lipohypertrophy". This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints w...
What is the current status of trial NCT04019197?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2019-05-16. Estimated completion is 2026-02-28.
What conditions does trial NCT04019197 study?
This clinical trial studies the following conditions: Obesity, HIV/AIDS, Lipohypertrophy.
What interventions are being tested in trial NCT04019197?
The interventions under investigation include: Placebo (DRUG), Semaglutide Injectable Product (DRUG).
Who is sponsoring clinical trial NCT04019197?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04019197 being conducted?
This trial has 2 study locations across Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.